Jaclyn Bosco, Sr Director, is the Global Scientific Head of Epidemiology and Biostatistics. She works with customers to develop strategies for using non-interventional study methods for real-world evidence generation to support the safety and effectiveness of drugs, biologics and biosimilars, and devices. She is experienced in helping customers refine their research questions based on various stakeholder needs, identifying the best approach for capturing data on a global scale as well applying local approaches to address market-specific needs, and designing and executing both primary and secondary data studies including medical chart review studies, patient registries, pregnancy registries, and comparative effectiveness and safety research studies. She has over 15 years of practical experience leading noninterventional research studies, and has conducted studies across the globe including North America, Europe, and Asia-Pacific regions. Dr. Bosco is responsible for scientific oversight, primarily in the areas of the design, analysis, and interpretation of non-interventional studies of comparative safety and effectiveness of medical treatments. She leads a global team of Epidemiologists and Outcomes Researchers and possesses considerable expertise in the application of epidemiologic methods to studies including propensity scoring, instrumental variable methods, bias analysis, and other methods for addressing bias in non-interventional studies. She is an epidemiology methods advisor on Scientific Advisory Boards, publishes articles in various leading peer-reviewed journals, presents at international and national meetings, reviews manuscripts and abstracts for high-impact journals and national conferences, co-authors book chapters, and teaches lectures in epidemiologic methods and biologics/biosimilars. Dr. Bosco is an Adjunct Assistant Professor of Epidemiology at Boston University School of Public Health, where she received her PhD in Epidemiology and MPH in Epidemiology and Biostatistics. She also completed her research fellowship with Dana Farber Cancer Institute/Harvard Medical School. She is currently a member of the International Society for Pharmacoepidemiology (ISPE) Education Committee (chair-elect) and Biologics & Biosimilars-SIG, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Society for Epidemiologic Research (SER), and American Association of Cancer Research (AACR) Molecular Epidemiology Working Group and Behavioural Sciences in Cancer Research Working Group